NCT03176173View on ClinicalTrials.gov

Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy

NAActive, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

November 24, 2021

Study Completion Date

May 1, 2026

Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
RADIATION

Image-guided Radiation Therapy

"Ablative treatment as 50 Gy in 5 or 10 fractions.~Non-ablative treatment as 27 Gy in 3 fractions, or 40 Gy in 10 fractions."

DRUG

Immunotherapy (physician's choice for standard of care immunotherapy)

Continue regular medical care immunotherapy. Other than being an anti-PD-1 or anti-PD-L1 immunotherapy, the agent, dose, and schedule is not specified by protocol.

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER

NCT03176173 - Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy | Biotech Hunter | Biotech Hunter